strategic review out , page-6

Muzza I honestly shat my pants when I read this.

Completing the evaluation of various clinical and regulatory pathways over the next several quarters for vapendavir to determine whether to independently continue its late-stage clinical development for the reduction of exacerbations caused by human rhinovirus (HRV) in patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD);


1. They decide now is the time to start working on Plan B i.e. development of the Phase 3 trial design. They should have been doing this when the program was put on the block in June 2012.

2. As far as I can tell, nobody has sought to license the program so if they decide not to "independently" develop the program, then the program is killed dead.